Search for: "SHIRE US INC." Results 61 - 80 of 101
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 Nov 2012, 5:00 am by Bexis
Pfizer Inc., 58 A.D.3d 138, 141 (N.Y. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech)   Products Adderall (Dextroamphetamine, Amphetamine) –… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US:… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US:… [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
11 Aug 2014, 4:24 am by Ben
Paragon Data Systems, Inc., Case No. 12-3025; -3058 (6th Cir., June 25, 2014) (Cleland, J., sitting by designation). [read post]
27 Mar 2009, 8:00 am
; no skulduggery involved in pharma enquiry submission switch says EPO (IPKat) (IAM) India: Public sector IP and socially responsible licensing (Spicy IP) India: Pharma lobby wants a probe into delayed orders (Spicy IP) UK: Euro costs in UK litigation: Actavis UK Ltd v Novartis AG (PatLit) US: Two biosimilars bills introduced in the House: HR 1427, the Promoting Innovation and Access to Life Saving Medicine Act; and H.R. 1548, the Pathway to BioSimilars Act (California Biotech Law Blog)… [read post]
5 Sep 2015, 11:58 am by Lawrence B. Ebert
A different three-judge panel on Sept. 1 said information of a clinical trial wasn’t evidence that could be used to challenge Biogen Inc. [read post]
12 Mar 2020, 6:49 am by Rebecca Tushnet
As the court pointed out, unlike with a drug or device, the consumer could read the book and decide not to use the advice, and the book would still have succeeded in its intended function: being read.Thus, when the ads for the book just describe the contents of the book, they’re protected to the same level as the book itself. [read post]
26 Dec 2017, 7:08 pm by Ben Vernia
  Shire Pharmaceuticals LLC paid $350 million to resolve allegations that Shire and the company it acquired in 2011, Advanced BioHealing (ABH), induced clinics and physicians to use or overuse its bioengineered human skin substitute by offering lavish dinners, drinks, entertainment and travel; medical equipment and supplies; unwarranted payments for purported speaking engagements and bogus case studies; and cash, credits and rebates. [read post]
15 Dec 2010, 2:17 am by Kelly
General Coming soon: International Classification of traditional medicine by WHO (Spicy IP) Teva Pharma uses online game to promote generic substitution (Patent Baristas) Australia: APO: Success of phase 3 trials ‘obvious’ in view of phase 1 and 2: Genentec, Inc (Patentology) Brazil: Government support to impel Brazil generic market (GenericsWeb) EU: EPO Enlarged Board of Appeal decides Broccoli (G2/07) and Tomatoes (G1/08) – essentially biological breeding… [read post]
25 Jan 2007, 12:48 am
Anyway, take it from those of us who have been on the receiving end. [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge… [read post]
16 Sep 2009, 1:47 pm
(Allston, MA; Tae Yi, President) Black Trace, Inc. [read post]
6 Apr 2011, 12:18 am by Marie Louise
427/09 Generics (UK) Ltd v Synaptech Inc (The SPC Blog) Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement complaint against Watson following Para IV certification filing (Patent Docs) Thalomid (Thalidomide) – US: Decision in Lannett Thalomid bioequivalence study sample antitrust lawsuit could reignite debate on generic drug availability and REMS restrictions (FDA Law Blog) Yasmin (Drospirenone, Ethinylestradiol) – UK: Bayer Yasmin… [read post]
20 Jul 2011, 4:04 am by Marie Louise
: Supreme Court hearing Human Genome Sciences Inc v Eli Lilly and Company (IPKat) Nexium (Esomeprazole) – UK: EWHC: Ranbaxy wins declaration of non-infringement: Ranbaxy v AstraZeneca (IPKat) Olanzapine – Spain: Supreme Court hands down landmark judgment on doctrine of equivalents and TRIPS (Kluwer Patent Blog) OxyContin (Oxycodone) – US: Purdue files patent infringement suit against Sandoz in response to Para IV certification (Patent Docs) Prevacid (Lansoprazole)… [read post]